Assessment of the endothelial glycocalyx state in patients with axial spondyloarthritis associated with Crohn’s disease

Abstract

BACKGROUND: Epithelial barrier dysfunction, including their permeability increment, is supposed to be a pathogenetic link in the development of various immunoinflammatory diseases, including Crohn’s disease and axial spondyloarthritits. Endothelial permeability regulation is provided by both intercellular contacts and endothelial glycocalyx.

AIM: To study the microcirculatory state by measuring the endothelial glycocalyx thickness in patients with axial spondyloarthritits associated with Crohn’s disease. To identify an association between the endothelial glycocalyx thinning and the epithelial permeability severity in patients with Crohn’s disease, axial spondyloarthritits and their combination.

MATERIALS AND METHODS: 12 patients with axial spondyloarthritits associated with Crohn’s disease (group A), 22 patients with idiopathic axial spondyloarthritits (group B), 24 patients with Crohn’s disease (group C) and 16 healthy individuals (group D) were examined. The endothelial glycocalyx thickness was assessed in the sublingual region using dark-field microscopy. Fecal calprotectin and fecal zonulin was studied.

RESULTS: A statistically significant increase in the perfused boundary region high flow was found (p = 0.001), as well as the MicroVascular Health Score (p = 0.004) in group A compared with the control. In Group A, a positive correlation between perfused boundary region high flow and scores Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Metrology Index 10 (p < 0.05) was found; perfused boundary region 5–9 mµ correlated positively with the fecal calprotectin (p = 0.007). Perfused boundary region high flow measurement provides 77.1% accuracy for correct classification of axial spondyloarthritits associated with Crohn’s disease and idiopathic axial spondyloarthritits (p = 0.010). In group C, a positive correlation between fecal zonulin and perfused boundary region 5–9 mµ, 10–19 mµ, 5–25 mµ (p < 0.05) was also found.

CONCLUSIONS: The findings suggest that the patients with axial spondyloarthritits associated with Crohn’s disease have endothelial glycocalyx impairment; the detection of these abnormalities may be useful in assessing the disease integral activity and in the differential diagnosis of axial spondyloarthritits associated with Crohn’s disease and idiopathic axial spondyloarthritits. Further studies of microcirculation will allow better understanding of spondyloarthritis and inflammatory bowel diseases pathogenesis and improve the management of patients with these diseases.

Keywords

axial spondyloarthritis / inflammatory bowel diseases / Crohn’s disease / endothelial glycocalyx / epithelial permeability / fecal zonulin

References

[1] Clinical rheumatology. Guide for doctors. Ed. by V.I. Mazurov. 3rd ed. Moscow: E-noto, 2021. 696 p. (In Russ.)

[2] Клиническая ревматология. Руководство для врачей / под ред. В.И. Мазурова. 3-е изд., перераб. и доп. Москва: Е-ното, 2021. 696 с.

[3] Kuzin AV, Rumiantsev VG. Arthritis associated with the inflammatory intestinal diseases. Russian Journal of Evidence-Based Gastroenterology. 2014;3(2):32–35. (In Russ.) EDN: SXTOUZ

[4] Кузин А.В., Румянцев В.Г. Артриты, ассоциированные с воспалительными заболеваниями кишечника // Доказательная гастроэнтерология. 2014. Т. 3, № 2. С. 32–35. EDN: SXTOUZ

[5] Di Jiang C, Raine T. IBD considerations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20939410. doi: 10.1177/1759720X20939410

[6] Di Jiang C., Raine T. IBD considerations in spondyloarthritis // Ther Adv Musculoskelet Dis. 2020. Vol. 12. P. 1759720X20939410. doi: 10.1177/1759720X20939410

[7] Benfaremo D, Luchetti MM, Gabrielli A. Biomarkers in inflammatory bowel disease-associated spondyloarthritis: State of the art and unmet needs. J Immunol Res. 2019;2019:8630871. doi: 10.1155/2019/8630871

[8] Benfaremo D., Luchetti M.M., Gabrielli A. Biomarkers in inflammatory bowel disease-associated spondyloarthritis: State of the art and unmet needs // J Immunol Res. 2019. Vol. 2019. P. 8630871. doi: 10.1155/2019/8630871

[9] Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract. 2014;2014(3):291–308. doi: 10.5339/gcsp.2014.43

[10] Widmer R.J., Lerman A. Endothelial dysfunction and cardiovascular disease // Glob Cardiol Sci Pract. 2014. Vol. 2014, N. 3. P. 291–308. doi: 10.5339/gcsp.2014.43

[11] Marchenko VN, Shchukina OB, Davydov DA, et al. Endothelial dysfunction in axial spondyloarthritis associated with inflammatory bowel disease. Herald of North-Western State Medical University named after I.I. Mechnikov. 2022;14(4):17–32. (In Russ.) EDN: RPLPOO doi: 10.17816/mechnikov108408

[12] Марченко В.Н., Щукина О.Б., Давыдов Д.А., и др. Дисфункция эндотелия при аксиальном спондилоартрите, ассоциированном с воспалительным заболеванием кишечника // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2022. Т. 14, № 4. С. 17–32. EDN: RPLPOO doi: 10.17816/mechnikov108408

[13] Vlasov TD, Lazovskaya OA, Shimanski DA, et al. The endothelial glycocalyx: research methods and prospects for their use in endothelial dysfunction assessment. Regional Blood Circulation and Microcirculation. 2020;19(1):5–16. (In Russ.) EDN: YVHFXQ doi: 10.24884/1682-6655-2020-19-1-5-16

[14] Власов Т.Д., Лазовская О.А., Шиманьски Д.А., и др. Эндотелиальный гликокаликс: методы исследования и перспективы их применения при оценке дисфункции эндотелия // Регионарное кровообращение и микроциркуляция. 2020. Т. 19, № 1. С. 5–16. EDN: YVHFXQ doi: 10.24884/1682-6655-2020-19-1-5-16

[15] Chmielińska M, Olesińska M, Romanowska-Próchnicka K, Szukiewicz D. Haptoglobin and its related protein, zonulin-what is their role in spondyloarthropathy? J Clin Med. 2021;10(5):1131. doi: 10.3390/jcm10051131

[16] Chmielińska M., Olesińska M., Romanowska-Próchnicka K., Szukiewicz D. Haptoglobin and its related protein, zonulin-what is their role in spondyloarthropathy? // J Clin Med. 2021. Vol. 10, N. 5. P. 1131. doi: 10.3390/jcm10051131

[17] Simanenkov VI, Maev IV, Tkacheva ON, et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):121–278. (In Russ.). doi: 10.15829/1728-8800-2021-2758

[18] Симаненков В.И., Маев И.В., Ткачева О.Н., и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус // Кардиоваскулярная терапия и профилактика. 2021. Т. 20, № 1. С. 121–278. doi: 10.15829/1728-8800-2021-2758

[19] Simanenkov VI, Maev IV, Tkacheva ON, et al. Epithelial protective therapy in comorbid diseases. practical guidelines for physicians. Terapevticheskii arkhiv. 2022;94(8):6–22. (In Russ.) EDN: KSTVKZ doi: 10.26442/00403660.2022.08.201523

[20] Симаненков В.И., Маев И.В., Ткачева О.Н., и др. Эпителий-протективная терапия при коморбидных заболеваниях. Практические рекомендации для врачей // Терапевтический архив. 2022. Т. 94, № 8. С. 6–22. EDN: KSTVKZ doi: 10.26442/00403660.2022.08.201523

[21] Szymanska E, Szymanska S, Dadalski M, Kierkus J. Biological markers of disease activity in inflammatory bowel diseases. Prz Gastroenterol. 2023;18(2):141–147. doi: 10.5114/pg.2023.129412

[22] Szymanska E., Szymanska S., Dadalski M., Kierkus J. Biological markers of disease activity in inflammatory bowel diseases // Prz Gastroenterol. 2023. Vol. 18, N. 2. P. 141–147. doi: 10.5114/pg.2023.129412

[23] Lam PK, McBride A, Le DHT, et al. Visual and biochemical evidence of glycocalyx disruption in human dengue infection, and association with plasma leakage severity. Front Med (Lausanne). 2020;7:545813. doi: 10.3389/fmed.2020.545813

[24] Lam P.K., McBride A., Le D.H.T., et al. Visual and biochemical evidence of glycocalyx disruption in human dengue infection, and association with plasma leakage severity // Front Med (Lausanne). 2020. Vol. 7. P. 545813. doi: 10.3389/fmed.2020.545813

[25] Rovas A, Sackarnd J, Rossaint J, et al. Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study. Crit Care. 2021;25(1):112. doi: 10.1186/s13054-021-03520-w

[26] Rovas A., Sackarnd J., Rossaint J., et al. Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study // Crit Care. 2021. Vol. 25, N. 1. P. 112. doi: 10.1186/s13054-021-03520-w

[27] Triantafyllou C, Nikolaou M, Ikonomidis I, et al. Effects of anti-inflammatory treatment and surgical intervention on endothelial glycocalyx, peripheral and coronary microcirculatory function and myocardial deformation in inflammatory bowel disease patients: a two-arms two-stage clinical trial. Diagnostics (Basel). 2021;11(6):993. doi: 10.3390/diagnostics11060993

[28] Triantafyllou C., Nikolaou M., Ikonomidis I., et al. Effects of anti-inflammatory treatment and surgical intervention on endothelial glycocalyx, peripheral and coronary microcirculatory function and myocardial deformation in inflammatory bowel disease patients: a two-arms two-stage clinical trial // Diagnostics (Basel). 2021. Vol. 11, N. 6. P. 993. doi: 10.3390/diagnostics11060993

[29] Malíčková K, Francová I, Lukáš M, et al. Fecal zonulin is elevated in Crohn’s disease and in cigarette smokers. Pract Lab Med. 2017;9:39–44. doi:10.1016/j.plabm.2017.09.001

[30] Malíčková K., Francová I., Lukáš M., et al. Fecal zonulin is elevated in Crohn’s disease and in cigarette smokers // Pract Lab Med. 2017. Vol. 9. P. 39–44. doi:10.1016/j.plabm.2017.09.001

[31] Caviglia GP, Dughera F, Ribaldone DG, et al. Serum zonulin in patients with inflammatory bowel disease: a pilot study. Minerva Med. 2019;110(2):95–100. doi: 10.23736/S0026-4806.18.05787-7

[32] Caviglia G.P., Dughera F., Ribaldone D.G., et al. Serum zonulin in patients with inflammatory bowel disease: a pilot study // Minerva Med. 2019. Vol. 110, N. 2. P. 95–100. doi: 10.23736/S0026-4806.18.05787-7

[33] Lacombe LAC, Matiollo C, Rosa JSD, et al. Factors associated with circulating zonulin in inflammatory bowel disease. Arq Gastroenterol. 2022;59(2):238–243. doi: 10.1590/S0004-2803.202202000-43

[34] Lacombe L.A.C., Matiollo C., Rosa J.S.D., et al. Factors associated with circulating zonulin in inflammatory bowel disease // Arq Gastroenterol. 2022. Vol. 59, N. 2. P. 238–243. doi: 10.1590/S0004-2803.202202000-43

RIGHTS & PERMISSIONS

Eco-Vector